Linda Boxer

Clinical Focus

• Cancer> Hematology
• Hematology
• Multiple Myeloma
• Multiple Myeloma - Medical Oncology
• Plasmacytoma

Administrative Appointments

• Chief, Division of Hematology, Stanford University School of Medicine (2004 - present)

Professional Education

Postdoctoral Advisees

Tamara Dunn,  Brian Jonas,  James McClellan,  Huong Nguyen,  Alexander Ungewickell

Graduate & Fellowship Program Affiliations

• Cancer Biology

Internet Links

• L. Boxer lab site

Current Research Interests

We are studying the transcriptional deregulation of several oncogenes in human hematologic malignancies.

Activation of c-myc in Burkitt's lymphoma: We are examining the transcriptional deregulation of the translocated c-myc gene and the silencing of the normal c-myc gene in Burkitt's lymphoma. We are looking at the c-myc promoter and regions of the immunoglobulin locus that are responsible for the deregulation of the translocated c-myc gene. Several model systems have been designed.

Activation of bcl-2 in hematologic malignancies: In lymphomas with the t(14;18) translocation, the bcl-2 gene is translocated to the immunoglobulin locus and expressed at high levels. We are studying the mechanism of activation at a molecular level in human lymphoma tissue. We have also developed a model system to determine which region of the immunoglobulin locus is responsible for the activation of the translocated bcl-2 gene.

Expression profiling in ALL: We are examining gene expression profiles in acute lymphoblastic leukemia in response to chemotherapeutic agents.

Publications

• The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells. Xiang H, Noonan EJ, Wang J, Duan H, Ma L, Michie S, Boxer LM. Leukemia. 2011; 25 (9): 1484-93
• Functional long-range interactions of the IgH 3' enhancers with the bcl-2 promoter region in t(14;18) lymphoma cells. Duan H, Xiang H, Ma L, Boxer LM. Oncogene. 2008; 27 (53): 6720-8
• Activation of the c-myc p1 promoter in Burkitt's lymphoma by the hs3 immunoglobulin heavy-chain gene enhancer. Hu HM, Kanda K, Zhang L, Boxer LM. Leukemia. 2007; 21 (4): 747-53
• Protein/DNA arrays identify nitric oxide-regulated cis-element and trans-factor activities some of which govern neuroblastoma cell viability. Dhakshinamoorthy S, Sridharan SR, Li L, Ng PY, Boxer LM, Porter AG. Nucleic Acids Res. 2007; 35 (16): 5439-51
• The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells. Duan H, Heckman CA, Boxer LM. Oncogene. 2007; 26 (18): 2635-41